Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
MM-691: Phase 3 AQUILA Study of Daratumumab Monotherapy Versus Active Monitoring in Patients With High-Risk Smoldering Multiple Myeloma (SMM)
Meletios A Dimopoulos, Peter W. Voorhees, F. Hellem Schjesvold, Yaël C. Cohen, Vânia Hungria, Irwindeep Sandhu, Jindriska Lindsay, Ross Baker, Kenshi Suzuki, Hiroshi Kosugi, Mark‐David Levin, Meral Beksac, Keith Stockerl‐Goldstein, Albert Oriol, Gábor Mikala, Gonzalo Garate, Koen Theunissen, Ivan Špıčka, Anne K. Mylin, Sara Galimberti, Katarina Uttervall, Bartosz Puła, Eva Medvedova, Andrew J. Cowan, Philippe Moreau, María‐Victoria Mateos, Hartmut Goldschmidt, Tahamtan Ahmadi, Linlin Sha, Annelore Cortoos, Eva G. Katz, Els Rousseau, Liang Li, Robyn M. Dennis, Robin Carson, S. Vincent Rajkumar (2025). MM-691: Phase 3 AQUILA Study of Daratumumab Monotherapy Versus Active Monitoring in Patients With High-Risk Smoldering Multiple Myeloma (SMM). , 25, DOI: https://doi.org/10.1016/s2152-2650(25)02630-8.
Article20 days agoPOSTER: MM-691 Phase 3 AQUILA Study of Daratumumab Monotherapy Versus Active Monitoring in Patients With High-Risk Smoldering Multiple Myeloma (SMM)
Meletios A Dimopoulos, Peter W. Voorhees, F. Hellem Schjesvold, Yaël C. Cohen, Vânia Hungria, Irwindeep Sandhu, Jindriska Lindsay, Ross Baker, Kenshi Suzuki, Hiroshi Kosugi, Mark‐David Levin, Meral Beksac, Keith Stockerl‐Goldstein, Albert Oriol, Gábor Mikala, Gonzalo Garate, Koen Theunissen, Ivan Špıčka, Anne K. Mylin, Sara Galimberti, Katarina Uttervall, Bartosz Puła, Eva Medvedova, Andrew J. Cowan, Philippe Moreau, María‐Victoria Mateos, Hartmut Goldschmidt, Tahamtan Ahmadi, Linlin Sha, Annelore Cortoos, Eva G. Katz, Els Rousseau, Liang Li, Robyn M. Dennis, Robin Carson, S. Vincent Rajkumar (2025). POSTER: MM-691 Phase 3 AQUILA Study of Daratumumab Monotherapy Versus Active Monitoring in Patients With High-Risk Smoldering Multiple Myeloma (SMM). , 25, DOI: https://doi.org/10.1016/s2152-2650(25)01280-7.
Article20 days agoIsatuximab (Isa) subcutaneous (SC) via an on-body delivery system (OBDS) vs Isa intravenous (IV), plus pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma (RRMM): Results of the randomized, non-inferiority, phase 3 IRAKLIA study.
Sikander Ailawadhi, Ivan Špıčka, Jin Lu, Albert Oriol, Silvia Ling, Fredrik Schjesvold, Alejandro Berkovits, Marek Hus, Meletios A Dimopoulos, Péter Rajnics, Vânia Hungria, Maria Del Rosario Custidiano, Gurdeep Parmar, Xavier P. Leleu, Tondre T. Buck, Jiří Minařík, Rick Zhang, Dorothée Sémiond, Maya Stefanova-Urena, Philippe Moreau (2025). Isatuximab (Isa) subcutaneous (SC) via an on-body delivery system (OBDS) vs Isa intravenous (IV), plus pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma (RRMM): Results of the randomized, non-inferiority, phase 3 IRAKLIA study.. , 43(16_suppl), DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.7506.
Article20 days agoIsatuximab subcutaneous by on-body injector in Relapsed/Refractory multiple myeloma in the Phase 3 iraklia study: Effect of body weight on pharmacokinetics and clinical outcome
Jin Lu, Albert Oriol, Alejandro Berkovits, Andrew Spencer, César Cinesi Gómez, Chunrui Li, Claudio Cerchione, Fei Li, Fredrik Schjesvold, Gurdeep Parmar, Ivan Špıčka, Marek Hus, Maria Del Rosario Custidiano, Meletios A Dimopoulos, Péter Rajnics, Sevgi Kalayoğlu Beşışık, Sikander Ailawadhi, Silvia Ling, Vânia Hungria, Xavier Leleu, Florence Suzan Teisserenc, Maya Stefanova-Urena, Rick Zhang, Victorine Koch, Dorothée Sémiond (2025). Isatuximab subcutaneous by on-body injector in Relapsed/Refractory multiple myeloma in the Phase 3 iraklia study: Effect of body weight on pharmacokinetics and clinical outcome. , 146(Supplement 1), DOI: https://doi.org/10.1182/blood-2025-5812.
Article20 days agoDeep responses and durable outcomes in patients treated with belantamab mafodotin plus pomalidomide and dexamethasone from long-term follow-up of the Phase 3 dreamm-8 study
Suzanne Trudel, Meral Beksac, Luděk Pour, Sosana Delimpasi, Vladimir Vorobyev, Hang Quach, Ivan Špıčka, Jakub Radocha, Paweł Robak, Kihyun Kım, Michèle Cavo, Kazuhito Suzuki, S. Yousuf Zafar, Ainslee Moore, Michael Duggan, Kristin Morris, Amy Phillips-Jones, Margaret Polinkovsky, Jayleen Grams, Ianire Garrobo-Calleja, Elisabet E. Manasanch, Brandon E. Kremer, Joanna Opalińska, María‐Victoria Mateos, Meletios A Dimopoulos (2025). Deep responses and durable outcomes in patients treated with belantamab mafodotin plus pomalidomide and dexamethasone from long-term follow-up of the Phase 3 dreamm-8 study. , 146(Supplement 1), DOI: https://doi.org/10.1182/blood-2025-2264.
Article20 days ago